Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24697314 | 0.92 | GLP1R (0.40) | GLP1RCCKBR | |
| SCHEMBL21287290 | 0.91 | GLP1R (0.42) | GLP1RTLR2LPAR3 | |
| SCHEMBL21393232 | 0.91 | GLP1R (0.40) | GLP1RTLR2MEN1KMT2A | |
| SCHEMBL21287666 | 0.89 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL18715475 | 0.85 | GLP1R (0.48) | GLP1RTLR2CCKBRMEN1KMT2A | |
| SCHEMBL20800942 | 0.84 | GLP1R (0.42) | GLP1RTLR2LPAR3 | |
| SCHEMBL20800989 | 0.81 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL20375511 | 0.81 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL20375520 | 0.80 | GLP1R (0.40) | GLP1RTLR2 | |
| SCHEMBL20017564 | 0.80 | GLP1R (0.46) | GLP1RTLR2LPAR3SYKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885TLR2 1481/4885CCKBR 2661/4885 |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885TLR2 1481/4885CCKBR 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.